NASDAQ · CPRX
Healthcare · Biotechnology
$31.49
Up+$0.00 (+0.00%)
Updated Oct 31, 2026, 4:33 AM
SID Score
7.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance · CPRX
1M range · 0 trading sessions · Daily adjusted prices
CPRX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CPRX.
Company
Market Activity
Research & News
CPRX research
Company profile and research snapshot.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 28, 2026 | HC Wainwright & Co. | Neutral | — |
| May 8, 2026 | Citigroup | Neutral | — |
| May 7, 2026 | Stephens & Co. | Equal-Weight | — |
| Mar 3, 2026 | Citigroup | Buy | — |
| Nov 7, 2025 | Citigroup | Buy | — |
No generated briefing is available yet.
ChartMill · Jul 15, 2026
This analysis highlights Catalyst Pharmaceuticals (CPRX), flagged by a screen combining accelerating growth with a bullish technical setup. The stock boasts strong fundamentals (8/10) and a perfect technical rating (10/10), showing consolidation near a key resistance level for a potential breakout.
ChartMill · Jul 10, 2026
Catalyst Pharmaceuticals (CPRX) scores 8/10 as a GARP stock with strong growth, reasonable valuation, and excellent financial health, making it a solid affordable growth investment.
Benzinga · Jul 9, 2026
https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20260709-1484347/1484347_cprx6.pdf
ChartMill · Jul 2, 2026
Catalyst Pharmaceuticals (CPRX) offers strong value with a P/E of 18.07, debt-free balance sheet, 37% profit margin, and 25% expected EPS growth, scoring 8/10 overall.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CPRX.
